Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Debiopharm honors cancer research in Lausanne

11.10.2006
The first Debiopharm Life Sciences Award will be presented to Spanish researcher Dr. Eduard Batlle during the 6th annual ISREC cancer research conference in Lausanne, Switzerland. This young scientist and his institute will receive 100,000 francs for his outstanding contributions to cancer research.

The award will be presented Wednesday, October 11, as part of the conference co-organized by EPFL (Ecole Polytechnique Federale deLausanne) and ISREC (Swiss Institute for Experimental Cancer Research) and held on the EPFL campus.

With one foot firmly in fundamental research and the other in clinical work, Eduard Batlle has concentrated his efforts over the past decade on elucidating the mechanisms underlying the onset and progression of colorectal cancer. His independent research in three different areas of colorectal cancer – the study of intestinal stem cells and their malignant counterparts, identification of molecules that prevent malignancy of colorectal tumors, and identification of the genetic components involved in the spread of cancer cells to the liver -- represents an important contribution to our understanding of this deadly cancer. His published articles have been cited more than a thousand times, appearing in journals such as Nature, Nature Cell Biology and Cell. He is also the holder of a patent that is currently being commercially developed by two companies.

Since 2004, Eduard Batlle has led the oncology group at Barcelona’s Biomedical Research Institute (IRB) and is a professor in the Catalan Institute for Research and Advanced Studies. He held postdoctoral research positions in Germany at the University of Marburg and in the Hubrecht Laboratory of the Netherlands Institute for Developmental Biology. He specializes in the areas of molecular biology and colorectal cancer.

POTENTIAL FOR THERAPY

The purpose of the Debiopharm Life Sciences Award is to mentor and motivate innovative European life sciences researchers under the age of 40; this year, the prize is awarded for cancer research. The research must demonstrate innovative vision and originality and have high potential for therapeutic and commercial applications. The jury was composed of three representatives of Debiopharm including Rolland-Yves Mauvernay, the company’s President and Founder; three EPFL professors, including EPFL President Patrick Aebischer; and two external experts. The jury expressed admiration for the « extremely high level » of the candidates.

The Lausanne-based company Debiopharm, founded in 1979, is an independent drug-development company specializing in oncology and serious medical conditions. The company works closely with universities, research institutions, biotech firms or pharmaceutical companies to identify compounds with promising in-vivo results that could lead to new pharmaceutical products. With its considerable expertise and proven track record, Debiopharm shepherds potential products all the way through to the treatment phase. The company is known in particular for having several products such as Eloxatin®, treatment of choice for colorectal cancer, and Decapeptyl® and Trelstar® for prostate cancer treatment. These products are commercialized by pharmaceutical companies such as sanofi-aventis and Watson Pharmaceuticals, Inc.

- For additional information, contact: Dietrich Reinhard, EPFL School of Life Sciences; tel: 021 693 16 43, e-mail: dietrich.reinhard@epfl.ch

- The official presentation ceremony will take place October 11 at 6 :45 pm at EPFL in room SG1, in the presence of Rolland-Yves Mauvernay, Founder and President of Debiopharm and Patrick Aebischer, President of EPFL.

Mary Parlange | alfa
Further information:
http://www.epfl.ch

More articles from Health and Medicine:

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

nachricht High speed video recording precisely measures blood cell velocity
15.11.2017 | ITMO University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>